Holen Sie sich die Stockscreener-App
2.12
98.13%
1.05
Handel nachbörslich:
2.05
-0.07
-3.30%
Bioaffinity Technologies Inc Aktie (BIAF) Neueste Nachrichten
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Benzinga
bioAffinity Technologies jumps 124% as it touts record 2025 CyPath Lung growth and outlines expansion plans - Quiver Quantitative
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth - Benzinga
bioAffinity Technologies Expands Lung Cancer Detection Initiatives - StocksToTrade
BioAffinity Technologies Shakes Up Diagnostics Field with Innovative Clinical Initiatives - timothysykes.com
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Benzinga
BIAF: CyPath® Lung test sales surged 99% in 2025, driving record revenue and future growth momentum - TradingView
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
bioAffinity Technologies reports 2025 financial results By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung - itemonline.com
BIAF vs. GH: Which cancer detection stock is the better buy now? - MSN
bioAffinity launches 2,000-patient study for noninvasive lung cancer test - Mugglehead Investment Magazine
Volume Recap: Can bioAffinity Technologies Inc lead its sector in growth2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Study Begins for bioAffinity Technologies’ CyPath Lung Cancer Diagnostic - Medical Product Outsourcing
CyPath Lung Expands Diagnostic Capabilities as bioAffinity Grows Board - StocksToTrade
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Non - pharmiweb.com
bioAffinity Launches Major Lung Cancer Detection Study - TipRanks
BioAffinity Technologies initiates clinical study for CyPath Lung - TipRanks
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic - The Joplin Globe
Aug Ideas: Will bioAffinity Technologies Inc. Equity Warrant stock split attract more investorsJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - Naître et grandir
bioAffinity Announces Upcoming Departure of Two Board Directors - TipRanks
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? - Finviz
bioAffinity Technologies, Inc. (BIAFW) Competitors - Meyka
bioAffinity presents asthma therapy matching research at AAAAI - Investing.com
bioAffinity Showcases Sputum-Based Platform for Personalized Asthma Care - TipRanks
bioAffinity presents asthma therapy matching research at AAAAI By Investing.com - Investing.com Australia
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study - mx.advfn.com
bioAffinity presents poster showing sputum test can ID receptors for leading asthma biologics - TradingView
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients - ChartMill
BIAFW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is bioAffinity Technologies Inc. affected by consumer sentimentJuly 2025 Recap & Safe Capital Growth Tips - mfd.ru
Is bioAffinity Technologies Inc stock heavily shorted2025 Geopolitical Influence & Verified Swing Trading Watchlists - baoquankhu1.vn
bioAffinity Technologies, Inc.Common Stock (NQ: BIAF - The Chronicle-Journal
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
bioAffinity launches study to test lung cancer diagnostic By Investing.com - Investing.com Australia
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test - BioSpace
bioAffinity launches study to test lung cancer diagnostic - Investing.com
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample - PharmiWeb.com
bioAffinity Launches New CyPath Lung Validation Study - TipRanks
Bioaffinity announces validation study for lung cancer test - marketscreener.com
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum - MSN
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 13.8% – Here’s What Happened - Defense World
Buyback Watch: Is bioAffinity Technologies Inc Equity Warrant stock overvalued or fairly pricedNew Guidance & Technical Pattern Based Buy Signals - baoquankhu1.vn
Can bioAffinity Technologies Inc. Equity Warrant weather a recessionTrade Analysis Summary & Reliable Volume Spike Trade Alerts - mfd.ru
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer - BioSpace
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Bur - PharmiWeb.com
bioAffinity Highlights CyPath Lung Case Study in Diagnostics - TipRanks
BioAffinity Technologies, Inc. Releases New Clinical Study Results - marketscreener.com
bioAffinity Highlights CyPath Lung Clinical Utility in Surveillance - TipRanks
Setup Watch: What is bioAffinity Technologies Inc Equity Warrants valuation compared to sectorForecast Cut & Precise Swing Trade Alerts - baoquankhu1.vn
How bioAffinity Technologies Inc. Equity Warrant stock performs in weak economyMarket Sentiment Summary & Risk Controlled Daily Trade Plans - mfd.ru
Is bioAffinity Technologies Inc.’s growth already priced in - mfd.ru
BIAF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Recap: Will bioAffinity Technologies Inc outperform tech stocksTrade Ideas & Technical Buy Zone Confirmations - baoquankhu1.vn
0.34%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):